

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

5,300

Open access books available

132,000

International authors and editors

160M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Cell Therapy and Tissular Engineering to Regenerate Articular Cartilage

Silvia M^a Díaz Prado^{1,2}, Isaac Fuentes Boquete^{1,2} and Francisco J Blanco^{2,3}

¹*Department of Medicine. INIBIC-University of A Coruña*

²*CIBER-BBN-Cellular Therapy Area*

³*INIBIC-Hospital Universitario A Coruña
Spain*

1. Introduction

Osteoarthritis (OA) is a degenerative joint disease characterized by deterioration in the integrity of hyaline cartilage and subchondral bone (Ishiguro et al., 2002). OA is the most common articular pathology and the most frequent cause of disability. Genetic, metabolic and physical factors interact in the pathogenesis of OA producing cartilage damage. The incidence of OA is directly related to age and is expected to increase along with the median age of the population (Brooks, 2002).

The capacity for the self-repair of articular cartilage is very limited, mainly because it is an avascular tissue (Mankin, 1982; Resinger et al., 2004; Fuentes-Boquete et al., 2008). Consequently, progenitor cells in blood and marrow cannot enter the damaged region to influence or contribute to the reparative process (Steinert et al., 2007).

There are a lack of reliable techniques and methods to stimulate growth of new tissue to treat degenerative diseases and trauma (Wong et al., 2005).

Modalities of cellular therapy to repair focal articular cartilage defects include the implantation of cells with chondrogenic capacity (Koga et al., 2008) and creating access to the bone-marrow. Of the numerous treatments available nowadays, no technique has yet been able to consistently regenerate normal hyaline cartilage. Current treatments generate a fibrocartilaginous tissue that is different from hyaline articular cartilage. To avoid the need for prosthetic replacement, different cell treatments have been developed with the aim of forming a repair tissue with structural, biochemical, and functional characteristics equivalent to those of natural articular cartilage (Fuentes-Boquete et al., 2007). This review summarizes the options for treatment of articular cartilage defects from both the experimental and clinical perspective (Fig. 1).

2. Perforation of the subchondral bone

This treatment is one of the most popular marrow-stimulating techniques based on the principle of inducing invasion of mesenchymal progenitor cells from the underlying subchondral bone to the lesion site, in order to initiate cartilage repair (Pelttari et al., 2009). This minimally invasive procedure has a low cost and is currently being used as the first treatment in patients not treated of cartilage defects. When the defect affecting the cartilage

penetrates to the bone and bone marrow spaces (osteochondral injury), mesenchymal cells from the bone marrow migrate with the hemorrhage and remain in the blood clot filling the defect, and are differentiated into articular chondrocytes thus been responsible for the repair of the defect (Fig. 2) (Shapiro et al., 1993). The opening of subchondral vascular spaces is utilized for several surgical strategies, such as arthroscopic abrasion (Friedman et al., 1984), subchondral drilling (Muller & Kohn, 1999), spongialization (Ficat et al., 1979) and microfracture (which produces the best results) (Steadman et al., 1999). In most cases, bone is formed in the bony defect and fibrocartilaginous tissue is formed in the chondral lesion (Johnson, 1986; Buckwalter & Mankin, 1998). In the case of large osteochondral defects, the ability to spontaneously repair the damage is negligible. On the contrary, if the chondral defect is small, articular cartilage can be completely repaired in full. The critical size of the lesion so that it will self-repair remains unknown.




Fig. 1. Different treatments of articular cartilage defects.

The outcome of these procedures is highly variable and frequently results in repair tissue composed of fibrocartilage with some limitations in quality and duration as compared to native hyaline cartilage (Pelttari et al., 2009). Experimental studies in rabbits (Metsaranta et al., 1996; Menche et al., 1996) and dogs (Altman et al., 1992) have shown that the repair tissue generated by these processes is fibrocartilaginous in nature, differing from hyaline articular cartilage in biochemical composition, structural organization, durability and biomechanical properties, and degenerates over time (Shapiro et al., 1993; Menche et al., 1996). In addition, the newly formed subchondral bone is thicker than the native subchondral bone (Qiu et al., 2003). The co-expression of types I and II collagens in repair tissue does not occur until one year following subchondral penetration (Furukawa et al., 1980). Clinical results, to some degree, contradict the findings relating to the quality of the repair tissue. For example, the treatment of knee osteochondral defects by microfracture has provided good clinical results after two years (Knutsen et al., 2004). This longevity, however, seems to be age-dependent, with the most persistent repair cartilage in patients under the age of 40 (Kreuz et al., 2006a). Although the initiation of a degenerative process for tissue repair has been described at 18 months after microfracture (Kreuz et al., 2006b), and 7 to 17 years after microfracture, improvement in articular function and pain relief were preserved (Steadman et al., 2003).




Fig. 2. Types of articular cartilage defects. In a partial defect the lesion includes cartilage tissue and part of the subchondral bone [A]. In a deep defect the lesion extends to the bone marrow [B]. C, uncalcified articular cartilage; t, tidemark; cc, calcified articular cartilage; sb, subchondral bone; bm, bone marrow.

3. Implants of periosteum and perichondrium

Tissue grafts have potential benefits since they allow the introduction of a new cell population embedded in an organic matrix, and reduces the development of fibrous adhesions between the articular surfaces before forming a new articular surface.

Periosteum and perichondrium contain mesenchymal stem cells (MSCs) that are capable of chondrogenesis (O'Driscoll et al., 2001; Duynstee et al., 2002). In particular, periosteum

consists of a fibrous outer layer, containing fibroblasts; and an inner layer or cambium, in direct contact with the bone, of higher cellular density, which contains MSCs.

Experimental studies in rabbits, indicated that the grafts of periosteum and perichondrium produce an incomplete filling of the chondral defect, and showed no significant differences between the two grafts in the quality of the repair tissue (Carranza-Bencano et al., 1999). In contrast, in a horse model, it was observed that chondrogenesis was more frequent and of greater magnitude in the grafts of periosteum than in perichondrium (Vachon et al., 1989). In both cases, these membrane implants forms a fibrocartilaginous repair tissue that does not seem to mature over time (Douchis et al., 2000; Trzeciak et al., 2006). However, the clinical effects of a perichondrium implant are similar those of subchondral perforation. At 10 years following either procedure there were no significant differences observed between their outcomes (Bouwmeester et al., 2002). However, the graft of perichondrium requires an additional intervention.

With age, decreases the chondrogenic potential of periosteum, decreasing the ability of MSCs to proliferate and differentiate into chondrocytes (O'Driscoll et al., 2001). This procedure has confirmed the improvement of joint function and pain relief (Korkala & Kuokkanen, 1995). The periosteum has the advantage of being readily available for transplantation. However, the technique of obtaining and management of periosteum is a critical step and determining the chondrogenic potential; if the cambium layer is not preserved, the procedure fails (O'Driscoll & Fitzsimmons, 2000).

At present, there is no sufficient evidence to justify the use periosteum and perichondrium implants in the treatment of chondral defects.

4. Osteoperiosteal implants

The cylinder of bone graft covered with periosteum has been used for the treatment of osteochondral defects. Although it has been reported that its clinical application produces improved joint function and pain relief (Korkala & Kuokkanen, 1995), studies in animals show a neosynthesized tissue with fibrous features (van Susante et al., 2003). When the graft is accompanied by chondrogenic inductors it acquires a fibrocartilaginous appearance (Jung et al., 2005). Also, bleeding from bone marrow spaces from the injury probably interferes with the repair action of the periosteum germ layer. In fact, in a rabbit model of osteoperiosteal implant it was found that nearly 67% of repair tissue cells were derived mainly from the bone marrow (Zarnett & Salter, 1989).

Osteochondral grafts have the advantage of providing matrix and viable chondrocytes that maintain this matrix (Czitrom et al., 1990; Schachar et al., 1992; Ohlendorf et al., 1996). In addition, it is possible to retrieve the subchondral bone and the contour of the joint of patients with osteochondral defects or articular incongruity. The articular cartilage transplantation as part of an osteochondral graft provides the decrease in joint pain (Beaver et al., 1992), perhaps by the replacement of the innervated area of the subchondral bone by a graft without innervation.

5. Mosaicplasty

Autologous mosaicplasty is considered to be a promising alternative for treatment of small to medium-sized focal chondral and osteochondral defects (Bartha et al., 2006). This technique involves the translocation of osteochondral cylinders, or plugs, from a low-

weight-bearing normal site to a high-weightbearing diseased site. The injured area is completely covered by means of the combination of different sizes of cylinders (Szerb et al., 2005). The donor sites spontaneously repair with mesenchymal stromal cells from the bone marrow to promote a new fibrocartilaginous tissue.

This procedure, which clinical application started in 1992 (Hangody & Karpati, 1994; Hangody et al., 2001) is considered a promising alternative for the treatment of chondral and osteochondral defects of small and medium-size load in synovial joints (Bartha et al., 2006). However, it is limited by several factors. The ideal diameter of the defect should range between 1 and 4 cm². In addition, clinical experience shows that age is a limiting factor, it is recommended to apply this technique only for patients under 50 years. Contraindications to the use of mosaicplasty include infection, tumor and rheumatoid arthritis (Szerb et al., 2005).

Arthroscopic evaluations at 5 (Chow et al., 2004) and 10 years (Hangody & Fules, 2003) after osteochondral cylinder implantation showed survival of the transplanted articular cartilage, congruency between opposing (treated and untreated) joint surfaces and fibrocartilaginous repair of the donor sites. However, if the osteochondral cylinders protrude above the surface, joint problems can arise. At 4 months post-surgery, patients with protruding cylinders experienced a "catching sensation" and some of these patients reported joint pain. Arthroscopic examinations of these cases revealed fissures in the osteochondral cylinders and fibrillation around the recipient site (Nakagawa et al., 2007).

The use of autologous mosaicplasty is limited by the defect size, which determines the number of osteochondral cylinders required. Thus, in large defects the best option is osteochondral allogenic transplantation. In addition, the implanted tissue comes from an area of low load, showing a thin thickness, a different histological structure and, therefore, a lower functional capacity for dealing with charge absorption.

The articular cartilage produced by this technique exhibits topographical variations in morphological, biochemical and physical properties (Xia et al., 2002; Rogers et al., 2006). Because the implanted tissue is harvested from a low-weight-bearing area, the cartilage is thinner and differs in histological structure from cartilage from high weight-bearing areas (Fragonas et al., 1998; Gomez et al., 2000).

6. Osteoarticular allotransplantation

Due to the avascular nature of chondrocytes and the fact that they are encapsulated in the extracellular matrix (ECM), articular cartilage is considered a privileged immunological tissue (Langer & Gross, 1974). Thus, the allogenic transplant may be the solution for problems arising from the autologous mosaicplasty (avoiding injury to the low load zone of cartilage, can produce a large number of osteochondral cylinders and these can come from the same load area). In fact, osteochondral allograft in knee has shown a good integration and provides a functional improvement at 2 years (McCulloch et al., 2007), showing a 85% of implant survival after more than 10 years after intervention (Gross et al., 2005).

7. Autologous chondrocyte implantation

A cell-based therapeutic alternative offering more effective repair of focal articular cartilage defects is autologous chondrocyte implantation (ACI) which was developed in a rabbit experimental model (Grande et al., 1987 & 1989). The first clinical application of this method

was performed by the group of Brittberg (Brittberg et al., 1994), which also demonstrated the successful repair of articular cartilage in rabbits transplanted with autologous chondrocytes (Brittberg et al., 1996). Currently the autologous chondrocyte implantation is a safe and effective therapeutic alternative to repair focal articular cartilage lesions (Pérez-Cachafeiro et al., 2010; Brittberg et al., 1994; Richardson et al., 1999; Peterson et al., 2000; Roberts et al., 2001). This procedure is also used for patients with osteochondritis dissecans (Peterson et al., 2002), but not for osteoarthritis joints. Because the results of this technique are highly age-dependent, the use of this procedure is recommended for patients younger than 55 years of age. The technique involves obtaining, by arthroscopy, articular cartilage explants from low-weight-bearing areas. Chondrocytes are then isolated and expanded *in vitro* to obtain a sufficient number of cells (approximately $10\text{-}12 \times 10^6$ cells) to introduce into the defect site, where they are expected to synthesize new cartilaginous matrix. In a second surgical intervention, the periosteum of the patient is removed from the proximal extremity and sutured to the edge of the cartilage injury, guiding the cambium layer towards the defect. This will close the defect cavity to retain the suspension of chondrocytes. Then, chondrocytes of the patient are resuspended in a liquid medium and injected into the cavity. A recent study assessed the efficacy and safety of ACI in 111 patients and demonstrated good clinical results in about 70% of the cases after 3 to 5 years (Pérez-Cachafeiro et al., 2010). Sometimes these autologous articular chondrocytes are introduced into the defect site as a cell suspension or in association with a supportive matrix (matrix-assisted ACI, MACI) (Pelttari et al., 2009). MACI uses a cell-seeded collagen matrix for treatment of cartilage defects. A prospective clinical investigation carried out in 38 patients with localized cartilage defects for a period of up to 5 years after surgery, showed that MACI represents a viable alternative for treatment of local cartilage defects of the knee (Behrens et al., 2006). The outcome of these chondrocyte-based techniques is generally quite good (Minas, 2001; Peterson et al., 2000) but in many cases results in the formation of non-hyaline cartilage repair tissue with inferior mechanical properties and limited durability (Pelttari et al., 2009). ACI has several technical limitations: *a*) obtaining cartilage explants requires an additional surgical intervention, adding to the articular cartilage damage that increases the osteoarthritic process (Marcacci et al., 2002); *b*) *in vitro* chondrocyte proliferation must be limited because the capacity to produce stable cartilage *in vivo* is gradually reduced when cell divisions are increased (Dell'Accio et al., 2001); *c*) aging reduces the cellular density of the cartilage, which impacts chondrocyte proliferation capacity *in vitro* (Menche et al., 1998) and the chondrogenic potential of the periosteum (O'Driscoll & Fitzsimmons, 2001), *d*) cell culture procedures take too long (3 to 6 weeks) and increase the risk of contamination, *e*) risk of leakage of transplanted chondrocytes from the cartilage defects, *f*) the effects of gravity causing the chondrocytes to sink to the dependent side of the defect, resulting in an unequal distribution of cells that hampers the homogenous regeneration of the cartilage (Díaz-Prado et al., 2010c; Sohn et al., 2002), *g*) not the least the reacquisition of phenotypes of dedifferentiated chondrocytes in a monolayer culture (Kimura et al., 1984; Benya & Shaffer, 1982) and *h*) hypertrophy of tissue (Steinwachs & Kreuz, 2007; Haddo et al., 2004). The use of periosteum membrane poses constraints and the need for wide surgical incision, hypertrophy of the periosteum peripheral implant and its potential for ectopic calcification. As an alternative it has been proposed the use of a membrane collagen type I/III (Haddo et al., 2004; Krishnan et al., 2006; Robertson et al., 2007). The use of both kinds of membranes shows no significant differences in the clinical assessment, although arthroscopic analysis

showed that after implantation of periosteum a substantial number of patients required a cleanup of the peripheral hypertrophy (Gooding et al., 2006).

In 1997, the American Society FDA (Food and Drug Administration) approved the cellular technology that uses autologous chondrocytes to repair articular cartilage lesions in the knee. This was the first type of cellular technology that was regulated by the industry for use in human transplantation (Brittberg et al., 2001).

The first article about ACI in humans appeared in 1994 (Brittberg et al., 1994). Clinical and arthroscopic evaluations of femoral implants showed good results after 2 years and the histological study of biopsies of the new tissue showed a similar appearance to hyaline cartilage in 11 of 15 cases of femoral implant. From this first approach further studies, based on clinical or arthroscopic evaluations, have demonstrated the durability of the implant. Thereby, after 5-11 years of treatment showed good or excellent clinical results in 51 of the 61 patients (Peterson et al., 2002). Histological analysis of the *de novo* formed tissue revealed some heterogeneity in the quality of the repair tissue. Of the 41 biopsies obtained one year following implantation, 10% consisted of hyaline cartilage; 24% consisted of a mixture of hyaline cartilage and fibrocartilage; 61% were entirely fibrocartilage and 5% consisted only of fibrous tissue (Tins et al., 2005).

Other studies at one year after implantation have shown that fibrocartilaginous morphology regions and hyaline morphology regions coexist in the same biopsy; both types having proteoglycans and type II collagen (Richardson et al., 1999; Roberts et al., 2001). Furthermore, aggrecanase activity was higher than metalloprotease activities in the fibrocartilaginous regions although both enzymes were found (Roberts et al., 2001). The expression of type IIA and IIB collagen mRNA was also detected (Briggs et al., 2003). These mRNA expressions seem be characteristic of the prechondrocytic state (type IIA) and differentiated chondrocytes (type IIB) (Nah et al., 2001). These results suggest that ACI induces the regeneration of articular cartilage, probably by the turnover and remodelling from an initial fibrocartilaginous matrix using enzymatic degradation and synthesis of type II collagen (Roberts et al., 2001). It is believed that this process continues for more than 24 months following the implantation (Peterson et al., 2000, Bentley et al., 2003) and takes place in three specific stages: cell proliferation (the first 6 weeks), transition (7 to 26 weeks) and remodeling (beyond 27 weeks) (Minas & Peterson, 1997).

8. Allograft transplantation and xenograft transplantation of chondrocytes

Other therapeutic alternatives are allograft transplantation (Wakitani et al., 1989; Rahfoth et al., 1998; Schreiber et al., 1999) and xenograft transplantation of chondrocytes (Fuentes-Boquete et al., 2004, Ramallal et al., 2004), that elude the damage added to the joint during autograft transplantation to obtain isolated chondrocytes. Allograft transplantation is constrained by the necessity for compatible donors and limitations on storage of cartilage or chondrocytes because cryopreservation reduces survival and proliferation of chondrocytes (Rendal-Vázquez et al., 2001). Xenograft transplantation may resolve some of these problems, but this therapeutic alternative has rarely been investigated. The immune barrier is an important objection to the use of both of these therapeutic procedures, although its application in articular cartilage presents fewer difficulties than in other tissues. Even though isolated chondrocytes result in immunogenic reaction, allograft transplantation of chondrocytes encapsulated in their ECM (Schreiber et al., 1999) or embedded in collagen gel (Wakitani et al., 1989) or agarose (Rahfoth et al., 1998) resulted in few or no rejection reactions. Notably,

xenotransplantation *in vivo* of cultured pig chondrocytes into rabbit chondral defects closed with periosteal membrane no signs of infiltration by immune cells (Ramallal et al., 2004).

9. Mesenchymal stem cells transplantation

Within the bone marrow stroma, a subset of non-hematopoietic cells referred to as MSCs exists. These cells can be isolated by adherence to plastic, expanded *ex vivo* and induced, both *in vitro* or *in vivo*, to terminally differentiate into multiple mesoderm-type lineages, including osteocytes, chondrocytes, adipocytes, tenocytes, myotubes, astrocytes and hematopoietic-supporting stroma (Barlow et al., 2008; Minguell et al., 2000; Caplan, 1991) and also into cell types of ectodermal (e.g., neurons) and endodermal (e.g., hepatocytes) origin (Pasquinelli et al., 2007). Furthermore, MSCs from different tissue sources can have biologic distinctions. For example, MSCs derived from bone marrow show a higher potential for osteogenic differentiation (Muraglia et al., 2000), while MSCs of synovial origin show a greater tendency toward chondrogenic differentiation (Djouad et al., 2005). Under identical culture conditions for differentiation, MSCs isolated from the synovial membrane show more chondrogenic potential than those derived from bone marrow, periosteum, skeletal muscle or adipose tissue (Sakaguchi et al., 2005). Studies of cartilage injury repair in animal models using MSCs embedded in collagen gel (Wakitani et al., 1989) or injected into defects closed with periosteal membrane (Im et al., 2001) indicate that MSCs can differentiate *in vivo* into a number of cell types in different biologic environments.

This procedure uses cells isolated from small tissue samples, proliferated in culture, to obtain the appropriate number for clinical applications. They can be implanted in the donor patient, obviating rejection problems. MSCs may be a tool for tissue repair that has the advantage of avoiding the problem of immunological rejection of the allotransplant and the ethical conflict of using embryonic stem cells. The recent use of autologous or allogenic stem cells has been suggested as an alternative therapeutic approach for treatment of cartilage defects (Jung et al., 2009). MSCs have the capability to self-renew and are responsible for repair and repopulation of damaged tissues in the adult (Hombach-Klonisch et al., 2008). For these reasons MSCs are a promising cell resource for tissue engineering and cell-based therapies (Pittenger, 2008). The interest in MSCs and their possible application in cell therapy have resulted in a better understanding of the basic biology of these cells. Due to the low number of MSCs that can be isolated from a tissue sample, culture expansion is necessary to obtain adequate cell numbers for clinical purposes and for the analysis of molecular mechanisms. However, the number of mitotic divisions of MSCs in culture must be limited because MSCs age during *in vitro* culture, causing a reduction in their proliferative capacity (Banfi et al., 2000; Bonab et al., 2006) and gradual loss of the potential for multiple differentiation (Banfi et al., 2000; Izadpanah et al., 2006). The conservation of phenotype and differentiation capacity of MSCs are proportional to telomerization (Abdallah et al., 2005). Telomeres are normally shortened in successive cell divisions, however, in embryonic stem cells the telomere length is restored by telomerase enzyme activity. On the other hand, MSCs lack (Zimmermann et al., 2003) adequate levels of telomerase activity to achieve telomeric restoration (Izadpanah et al., 2006; Parsch et al., 2004; Yanada et al., 2006). Patient age also influences the characteristics of MSCs because their proliferative capacity is reduced by aging (Stenderup et al., 2003).

Three criteria define all types of stem cells: self-renewal, multipotency and the ability to reconstitute a tissue *in vivo*. According to a recent proposal of the International Society for Cellular Therapy (Dominici et al., 2006), MSCs are multipotent nonhematopoietic

progenitors located within the stroma of the bone marrow and other organs that are phenotypically characterized by the expression of several markers (e.g., CD73, CD90, and CD105) and the lack of expression of CD14 or CD11b, CD19 or CD79 α , CD34, CD45 and HLA-DR surface molecules (Mrugala et al., 2009; Kastrinaki et al., 2008). Because there is no specific marker for MSCs, the principal criteria for identification are adherence to the plastic of the tissue culture flask, fibroblast-like morphology (Prockop, 1997), the prolonged capacity for proliferation in supportive media and the capacity to differentiate *in vitro* into cells of mesodermal origin (chondrocytes, adipocytes, osteoblasts). Furthermore, characteristics of MSCs are the absence of expression of typical hematopoietic antigens like CD34 and CD45, and the expression of surface markers like Stro-1, CD44, CD73, CD90, CD105 and CD166 (Pittenger et al., 1999).

Human MSCs, which are probably responsible for normal tissue renewal, as well as for response to injury (Tsai et al., 2007), have been isolated from several tissues, including bone marrow (Kastrinaki et al., 2008; Yoo et al., 1998), periosteum (Nakahara et al., 1990), perichondrium (Douchis et al., 1997), synovial membrane (De Bari et al., 2001; Fickert et al., 2003), articular cartilage (Alsalameh et al., 2004); connective tissue of dermis and skeletal muscle (Young et al., 2001), peripheral blood (Villaron et al., 2004; Kuznetsov et al., 2001; Zvaifler et al., 2000), adipose tissue (Zuk et al., 2001 & 2002), lung (In't Anker et al., 2003), liver (Le Blanc et al., 2005), amniotic fluid (You et al., 2008; Steigman & Fauza, 2007; Fauza, 2004), placenta (Barlow et al., 2008, Steigman & Fauza, 2007; Fauza, 2004; Matikainen & Laine, 2005), amniotic membrane (Díaz-Prado et al., 2010a & 2010b; Alviano et al., 2007), umbilical cord (Baksh et al., 2007) and umbilical cord blood (Mareschi et al., 2001). Although bone marrow is the usual source of MSCs, umbilical cord blood is emerging as an important reservoir for stem cells capable of differentiation into many cell types and possessing the advantages of immune status and relatively unshortened telomere length (McGuckin et al., 2005). Some countries have private and public stem cell banks from umbilical cord blood (UCB) for transplant programs or personal use (Samuel et al., 2008). Multipotent MSCs are a promising cell resource for tissue engineering and cell-based therapeutics because of their ability to self-renew and differentiate into specific functional cell types (Tsai et al., 2007). The list of tissues with the potential for tissue engineering is increasing because of recent progress in stem cell biology (Bianco & Robey, 2001).

In vitro (Pittenger et al., 1999; Majumdar et al., 1998; Muraglia et al., 2000) and *in vivo* (Gronthos et al., 2003) studies of clonally-derived MSCs demonstrated that the MSC population consists of subsets that have different expression of markers and different capacities for cellular differentiation. To improve the number of MSCs isolated from a tissue it is frequent to use a pre-plating technique that minimizes the number of contaminating fibroblasts in the culture (Richler & Yaffe, 1970). Also, MSCs show phenotypic and functional differences depending on their tissue of origin. For example, MSCs from bone marrow and synovial membrane have been differentiated by their gene expression profiles (Djouad et al., 2005).

Several studies have recently reported the migration of intraarticularly injected MSCs to the site of a cartilage injury to repair chondral defects. In a caprine model for osteoarthritis in which OA is induced by the complete excision of the medial meniscus and resection of the anterior cruciate ligament, the intraarticular injection of MSCs produced meniscus repair after 6 weeks; however, there was no evidence of cartilage or ligament repair (Murphy et al., 2003). This suggests that the injected MSCs migrated to the injured meniscus, but not the

damaged cartilage. The intraarticular injection of MSCs into rat knees, however, showed mobilization of these cells towards all injured tissues, including articular cartilage; the MSCs contributed to tissue regeneration (Nishimori et al., 2006; Agung et al., 2006).

In osteoarthritic knees, MSCs embedded in collagen gel were implanted into chondral defects and closed with periosteal membrane. After 42 weeks, arthroscopic and histological results were better than in osteoarthritic patients without implants, although there was no statistically significant improvement in clinical results (Wakitani et al., 2002). The use of MSCs to treat chondral lesions clinically has not been established, in part because the stages of chondrogenic differentiation of MSCs are not sufficiently defined. In addition, there are currently no protocols that ensure direct differentiation to the desired phenotype; the plasticity of the cells differentiated from MSCs can lead to undesirable phenotypic alterations (De Bari et al., 2004; Pelttari et al., 2006).

10. Scaffolds

The clinical outcome of the techniques described above underline the need of increase the quality of the synthesized repair tissue. To overcome some of the limitations of ACI, cell delivery supports can be used for cell transplantation. Recent research efforts have focused on tissue engineering as a promising approach for cartilage regeneration and repair (Kuo et al., 2006). Tissue engineering is a technique by which a living tissue can be reconstructed by associating the cells with biomaterials that provide a scaffold on which they can proliferate three-dimensionally, under physiological conditions (Iwasa et al., 2009). A biomaterial is any pharmacologically inert compound designed to be implanted or incorporated into the living system. Therefore cartilage tissue engineering is critically dependent on the selection of appropriate cells (differentiated or MSCs), suitable scaffolds for cell delivery and biological stimulation with chondrogenically bioactive molecules (Kuo et al., 2006). The transplantation of chondrocytes seeded on natural and synthetic scaffolds has been used for cartilage tissue engineering (Kuo et al., 2006). Regeneration of a hyaline-like repair tissue could be obtained after the implantation of a pre-engineering, functional cartilage tissue, instead of the delivery of a chondrocyte implantation (Pelttari et al., 2009). A major prerequisite for choosing a scaffold is the property of not producing toxic, injurious, carcinogenic, or immunological responses (either inflammation or rejection) in living tissue (Niknejad et al., 2008). New tissue regeneration should occur as the scaffold degrades, so the new tissue assumes the shape and size of the original scaffold. Design criteria for scaffolds include suitable mechanical strength and surface chemistry, ability to be processed in different shapes and sizes, and the ability to regulate cellular activities such as differentiation and proliferation (Kuo et al., 2006). Moreover, requirements for the biomaterials used as a scaffold include controlled biocompatibility, structurally and mechanically stable, permeability (allowing the exchange of nutrients and metabolites), suitable ligands for implanted cell attachment, must support the loading of an appropriate cell source to allow successful infiltration and attachment with appropriate bioactive molecules in order to promote cellular differentiation and maturation. Also, they must present readily integration with native cartilage, biodegradation into non-toxic products that can be replaced by host cells, initial stability and provide an excellent environment for cell and tissue growth and differentiation crucial to maintain cell function and development of new tissue. Scaffolds must also provide a stable temporary structure while cells seeded

within the biodegradable matrix synthesize a new and natural tissue (Frenkel & Di Cesare, 2004). Other important factors in the design of a scaffold are pore size, porosity, adaptive shape, mechanical integrity, the ability to be retained at the implantation site and cost efficiency.

A number of scaffolds have been developed and investigated, *in vitro* and *in vivo*, for potential use in tissue engineering and in particular for *in vitro* regeneration of cartilage tissues (Vinatier et al., 2009). Carriers have been marketed and various tissue-engineering techniques have been developed using chondrocytes seeded on biological matrices (Iwasa et al., 2009). For cartilage tissue engineering, scaffolding has been fabricated from both natural and synthetic polymers (Tuli et al., 2003), such as fibrous structures, porous sponges, woven or non-woven meshes and hydrogels (Kuo et al., 2006). Natural biomaterials, such as fibrin, collagen, agarose, alginate, hyaluronic acid or chitosan (Eyrich et al., 2007; Cao & Xu, 2008; Mouw et al., 2005; Lisignoli et al., 2006; Nettles et al., 2002) and synthetic biomaterials, such as poly-lactic glycolic acid (PLGA) (Han et al., 2008) and a polymeric nanofiber (Janjanin et al., 2008), are used alone or in different combinations to make scaffolds. Collagen and hyaluronan-based matrices are among the most popular natural scaffolds in clinical use nowadays, since they contain natural components of the hyaline cartilage. On the contrary, there is no clinical experience using scaffolds such as alginate, agarose and chitosan (Iwasa et al., 2009). Within each kind of biomaterial (natural and synthetic) there are many types of biomaterials that are being studied, with controversial results. The human amniotic membrane (HAM) is considered to be an important potential source for scaffolding material (Niknejad et al., 2008). The HAM possesses considerable advantages that are not shared by other natural or synthetic polymers. On the other hand, HAM has abundant natural cartilage components, which are important in the regulation and maintenance of normal chondrocyte metabolism (Jin et al., 2007); this suggests that the HAM is an excellent candidate for use as native scaffold for cartilage tissue engineering (Niknejad et al., 2008). Amnion allografts are widely applied in ophthalmology, plastic surgery, dermatology, and gynecology (Tejwani et al., 2007; Santos et al., 2005; Rinastiti et al., 2006; Meller et al., 2000; Morton & Dewhurst, 1986). A recent study demonstrated the potential use of the HAM as a scaffold to support human chondrocyte proliferation in cell therapy to repair human OA cartilage (Díaz-Prado et al., 2010c).

Experimental studies in animals with synthetic biomaterials showed disappointing results, since after 8 weeks of implantation, all animals suffered ulceration and loss of cartilage (Oka et al., 1997). The problem that arises with artificial biomaterials is that the implant is not interwoven with adjacent bone, leading to degradation of the recovered surface after only 2 or 3 months (Oka et al., 1997). In a study in rabbits with a biomaterial composed of collagen in which chondrocytes were seeded, a good proliferation and cell phenotype maintenance were shown; therefore good repair results were observed (Frenkel et al., 1997). One of the major limitations of the use of matrices is the size of the lesion (Nixon et al., 1993, Sams & Nixon, 1995, Sams et al., 1995). Despite the diffusion of new tissue-engineering techniques and the number of scaffolds that have been investigated, the ideal matrix material has not been identified. However, the clinical use of these materials is currently limited, mainly due to the risk of disease transmission and immunoreaction (Iwasa et al., 2009).

Mechanical and biological properties of biomaterials significantly influence chondrogenesis and the long-term maintenance of the structural integrity of the neo-formed tissue. The three-dimensional nature of the scaffolds promotes maintenance of rounded cell

morphology and the elevated expression of glycosaminoglycans and type II collagen (Nettles et al., 2002; Gong et al., 2008). Other advantage is that cell delivery supports may act as barrier to the invasion of the graft by fibroblasts, which may otherwise induce fibrous repair (Frenkel et al., 1997). Indeed, the presence of ECM around cells was reported to increase donor cell retention at the repair site and possibly protect the cells from environmental factors such as inflammatory molecules (Pelttari et al., 2009). The tissue-engineering methods with scaffolds including the arthroscopy technique are less invasive because there is no need to harvest periosteum (Iwasa et al., 2009). Other benefits of this methodology are: reduce surgical time, morbidity, and risk of periosteal hypertrophy and postsurgical adhesions substantially (Iwasa et al., 2009). However, scaffolding biomaterials have differing influences on the metabolism of host cells and, consequently, the quality of the tissue-engineered cartilage (Mouw et al., 2005, Jeon et al., 2007). For example, the use of chitosan, compared to PLGA, for cartilage tissue engineering produces a superior maintenance of structural integrity because the expression of type II collagen protein and mRNA became weaker over time in the PLGA group (Jeon et al., 2007). Scaffolds using hyaluronic acid are also being used with excellent clinical and histological results (Giannini et al., 2008).

11. Gene therapy

The introduction of genetic products into the field of tissue damage repair can enhance the process of articular cartilage restoration. The most obvious would be growth factors, proteinase inhibitors and cytokine antagonists. The gene therapy process involves the determination of the appropriate gene and cell type (chondrocytes, chondrogenic cells and cells of the synovial membrane) for the gene transfer, as well as the determination of the optimal vector to incorporate the cDNA (Trippel et al., 2004). Different anabolic factors, such as members of the TGF- β 3 (tumor growth factor beta 3), IGF (insulin growth factor), FGF (fibroblastic growth factor), and HGF (hepatocyte growth factor) superfamily, could induce chondrogenesis and the synthesis of ECM components, while anti-inflammatory molecules, such as interleukins (IL): IL-4, IL-10, IL-1Ra (IL-1 receptor antagonist), and TNFsR (tumor necrosis factor soluble receptor), could act as inhibitors of cartilage degradation (Gelse et al., 2003).

The synovial membrane seems to be useful as a target for chondroprotective therapies (Palmer et al., 2002). The viral transfection *in vivo* with the IL-1Ra gene in rheumatoid arthritis joints reduces the severity of the disease process in animal models (Gouze et al., 2003). Furthermore, this technique makes possible the safe intraarticular expression of the IL-1Ra gene (Evans et al., 2005 & 2001). Chondrocytes and MSCs are the preferred targets for the induction of chondrogenesis. Using animal models, the transplantation *in vivo* of MSCs transfected with BMP-2 (bone morphogenetic protein-2) cDNA produces improved chondral lesion repair with a higher production of proteoglycans and type II collagen compared to controls (Park et al., 2006).

12. Conclusion

Modalities of cellular therapy to repair focal articular cartilage defects include the implantation of cells with chondrogenic capacity and creating access to the bone-marrow. Of the numerous treatments available nowadays, no technique has yet been able to consistently

regenerate normal hyaline cartilage. The implantation of autologous chondrocytes and autologous mosaicplasty induces a better quality of articular cartilage whereas the use of stem cell implants is in an early experimental stage at this time. Currently the autologous chondrocyte implantation is the most effective therapeutic alternative to repair focal articular cartilage lesions although this procedure is also used for patients with osteochondritis dissecans but not for osteoarthritis joints. On the other hand the use of tissue-engineered grafts based on scaffolds seems to be as effective as conventional ACI clinically but there are no convincing evidences that scaffold techniques allow the maintenance of the chondrocyte phenotype and the homogeneous distribution of the cells. Therefore it has not verified that the technical and theoretical advantages of scaffold techniques have led to the better clinical and histological results compared with conventional ACI. Further studies would be needed to determine whether articular cartilage repair with scaffolds is the most adequate alternative to ACI.

13. Acknowledgements

This study was supported by grants: Servizo Galego de Saúde, Xunta de Galicia (PS07/84); Cátedra Bioiberica de la Universidade da Coruña; Instituto de Salud Carlos III CIBER BBN CB06-01-0040; Ministerio de Ciencia e Innovacion PLE2009-0144; Fondo de Investigacion Sanitaria-PI 08/2028 with participation of fundus from FEDER (European Community), Silvia Diaz-Prado is beneficiary of an Isidro Parga Pondal contract from Xunta de Galicia, A Coruna, Spain.

14. References

- Abdallah BM, Haack-Sorensen M, Burns JS, Elsnab B, Jakob F, Hokland P, Kassem M. (2005). Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. *Biochem Biophys Res Commun* 326:527-38.
- Agung M, Ochi M, Yanada S, Adachi N, Izuta Y, Yamasaki T, Toda K. (2006). Mobilization of bone marrow-derived mesenchymal stem cells into the injured tissues after intraarticular injection and their contribution to tissue regeneration. *Knee Surg Sports Traumatol Arthrosc* 14:1307-14.
- Alsalameh S, Amin R, Gemba T, Lotz M. (2004). Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. *Arthritis Rheum* 50:1522-32.
- Altman RD, Kates J, Chun LE, Dean DD, Eyre D. (1992). Preliminary observations of chondral abrasion in a canine model. *Ann Rheum Dis* 51:1056-62.
- Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, Lanzoni G, Cantoni S, Cavallini C, Bianchi F, Tazzari PL, Pasquinelli G, Foroni L, Ventura C, Grossi A, Bagnara GP. (2007). Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with ability to differentiate into endothelial cells *in vitro*. *BMC Dev Biol* 7:11.
- Baksh D, Yao R, Tuan RS. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. *Stem Cells* 25:1384-92.

- Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R. (2000). Proliferation kinetics and differentiation potential of *ex vivo* expanded human bone marrow stromal cells: Implications for their use in cell therapy. *Exp Hematol* 28:707-15.
- Barlow S, Brooke G, Chatterjee K, Price G, Pelekanos R, Rossetti T, Doody M, Venter D, Pain S, Gilshenan K, Atkinson K. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. *Stem Cells Dev* 17:1095-1108.
- Bartha L, Vajda A, Duska Z, Rahmeh H, Hangody L. (2006). Autologous osteochondral mosaicplasty grafting. *J Orthop Sports Phys Ther* 36:739-50.
- Beaver RJ, Mahomed M, Backstein D, Davis A, Zukor DJ, Gross AE. (1992). Fresh osteochondral allografts for post-traumatic defects in the knee. A survivorship analysis. *J Bone Joint Surg Br* 74:105-10.
- Behrens P, Bitter T, Kurz B, Russlies M. (2006). Matrix-associated autologous chondrocyte transplantation/implantation (MACT/MACI)- 5-year follow-up. *Knee* 13:194-202.
- Bentley G, Biant LC, Carrington RW, Akmal M, Goldberg A, Williams AM, Skinner JA, Pringle J. (2003). A prospective, randomised comparison of autologous chondrocyte implantation versus mosaicplasty for osteochondral defects in the knee. *J Bone Joint Surg Br* 85:223-30.
- Benya PD, Shaffer JD. (1982). Dedifferentiated chondrocytes re-express the differentiated collagen phenotype when cultured in agarose gels. *Cell* 30:215-24.
- Bianco P, Robey PG. (2001). Stem cells in tissue engineering. *Nature* 414:118-21.
- Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. (2006). Aging of mesenchymal stem cell *in vitro*. *BMC Cell Biol* 7:14-20.
- Bouwmeester PS, Kuijer R, Homminga GN, Bulstra SK, Geesink RG. (2002). A retrospective analysis of two independent prospective cartilage repair studies: autogenous perichondrial grafting versus subchondral drilling 10 years post-surgery. *J Orthop Res* 20:267-73.
- Briggs TW, Mahroof S, David LA, Flannelly J, Pringle J, Bayliss M. (2003). Histological evaluation of chondral defects after autologous chondrocyte implantation of the knee. *J Bone Joint Surg Br* 85:1077-83.
- Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. (1994). Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 331:889-95.
- Brittberg M, Nilsson A, Lindahl A, Ohlsson C, Peterson L. (1996). Rabbit articular cartilage defects treated with autologous cultured chondrocytes. *Clin Orthop Relat Res* (326):270-83.
- Brittberg M, Tallheden T, Sjögren-Jansson B, Lindahl A, Peterson L. (2001) Autologous chondrocytes used for articular cartilage repair: an update. *Clin Orthop Relat Res* (391 Suppl):S337-48.
- Brooks PM. (2002). Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. *Curr Opin Rheumatol* 14:573-7.
- Buckwalter JA, Mankin HJ. (1998). Articular cartilage: tissue design and chondrocyte-matrix interactions. *Instr Course Lect* 47: 477-86.
- Cao H, Xu SY. (2008). EDC/NHS-crosslinked type II collagen-chondroitin sulfate scaffold: characterization and *in vitro* evaluation. *J Mater Sci Mater Med* 19(2):567-75.
- Caplan AI. (1991). Mesenchymal stem cells. *J Orthop Res* 9:641-50.
- Carranza-Bencano A, Perez-Tinao M, Ballesteros-Vázquez P, Armas-Padrón JR, Hevia-Alonso A, Martos Crespo F. (1999). Comparative study of the reconstruction of articular cartilage defects with free costal perichondrial grafts and free tibial periosteal grafts: an experimental study on rabbits. *Calcif Tissue Int* 65:402-7.

- Chow JC, Hantes ME, Houle JB, Zalavras CG. (2004). Arthroscopic autogenous osteochondral transplantation for treating knee cartilage defects: a 2- to 5-year follow-up study. *Arthroscopy* 20:681-90.
- Czitrom AA, Keating S, Gross AE. (1990). The viability of articular cartilage in fresh osteochondral allografts after clinical transplantation. *J Bone Joint Surg Am* 72:574-81.
- De Bari C, Dell'Acio F, Tylzanowski P, Luyten FP. (2001). Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum* 44:1928-42.
- De Bari C, Dell'Accio F, Luyten FP. (2004). Failure of *in vitro* differentiated mesenchymal stem cells from the synovial membrane to form ectopic stable cartilage *in vivo*. *Arthritis Rheum* 50:142-50.
- Dell'Accio F, De Bari C, Luyten FP. (2001). Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage *in vivo*. *Arthritis Rheum* 44:1608-19.
- Díaz-Prado S, Muñños-López E, Hermida-Gómez T, Rendal-Vázquez ME, Fuentes-Boquete I, de Toro FJ, Blanco FJ. (2010a). Isolation and characterization of mesenchymal stem cells from human amniotic membrane. *Tissue Eng Part C Methods* Aug 1.
- Díaz-Prado S, Muñños-López E, Hermida-Gómez T, Rendal-Vázquez ME, Fuentes-Boquete I, de Toro FJ, Blanco FJ. (2010b). Multilineage differentiation potential of cells isolated from the human amniotic membrane. *J Cell Biochem* Jul 21.
- Díaz-Prado S, Rendal-Vázquez ME, Muñños López E, Hermida-Gómez T, Rodríguez-Cabarcos M, Fuentes-Boquete I, de Toro FJ, Blanco FJ. (2010c). Potential use of the human amniotic membrane as a scaffold in human articular cartilage repair. *Cell Tissue Bank* 11:183-95.
- Djouad F, Bony C, Häupl T, Uzé G, Lahlou N, Louis-Plence P, Apparailly F, Canovas F, Réme T, Sany J, Jorgensen C, Noël D. (2005). Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal cells. *Arthritis Res Ther* 7:1304-15.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 8:315-7.
- Douchis JS, Goomer RS, Harwood FL, Khatod M, Coutts RD, Amiel D. (1997). Chondrogenic phenotype of perichondrium-derived chondroprogenitor cells is influenced by transforming growth factor-beta 1. *J Orthop Res* 15:803-7.
- Douchis JS, Bae WC, Chen AC, Sah RL, Coutts RD, Amiel D. (2000). Cartilage repair with autogenic perichondrium cell and polylactic acid grafts. *Clin Orthop Relat Res* (377):248-64.
- Duynstee ML, Verwoerd-Verhoef HL, Verwoerd CD, Van Osch GJ. (2002). The dual role of perichondrium in cartilage wound healing. *Plast Reconstr Surg* 110:1073-9.
- Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Wasko MC, Tomaino M, Kang R, Muzzonigro TA, Elder EM, Whiteside TL, Watkins SC. (2001). Transfer and intraarticular expression of the IL-1Ra cDNA in human rheumatoid joints. *Arthritis Res* 3 (Suppl 1):P33.
- Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, Muzzonigro TA, Vogt M, Elder EM, Whiteside TL, Watkins SC, Herndon JH. (2005). Gene transfer to human joints: progress toward a gene therapy of arthritis. *Proc Natl Acad Sci USA* 102:8698-703.

- Eyrich D, Brandl F, Appel B, Wiese H, Maier G, Wenzel M, Staudenmaier R, Goepferich A, Blunk T. (2007). Long-term stable fibrin gels for cartilage engineering. *Biomaterials* 28:55-65.
- Fauza D. (2004). Amniotic fluid and placental stem cells. *Best Pract Res Clin Obstet Gynaecol* 18:877-91.
- Ficat RP, Ficat C, Gedeon P, Toussaint JB. (1979). Spongialization: a new treatment for diseased patellae. *Clin Orthop Rel Res* 144: 74-83.
- Fickert S, Fiedler J, Brenner RE. (2003). Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. *Osteoarthritis Cartilage* 11:790-800.
- Fragonas E, Mlynárik V, Jellús V, Micali F, Piras A, Toffanin R, Rizzo R, Vittur F. (1998). Correlation between biochemical composition and magnetic resonance appearance of articular cartilage. *Osteoarthritis Cartilage* 6:24-32.
- Frenkel SR, Toolan B, Menche D, Pitman MI, Pachence JM. (1997). Chondrocyte transplantation using a collagen bilayer matrix for cartilage repair. *J Bone Joint Surg Br* 79:831-6.
- Frenkel SR, Di Cesare PE. (2004). Scaffolds for articular cartilage repair. *Ann Biomed Eng* 32:26-34.
- Friedman MJ, Berasi CC, Fox JM, Del Pizzo W, Snyder SJ, Ferkel RD. (1984). Preliminary results with abrasion arthroplasty in the osteoarthritic knee. *Clin Orthop Rel Res* 182:200-5.
- Fuentes-Boquete I, López-Armada MJ, Maneiro E, Fernández-Sueiro JL, Caramés B, Galdo F, de Toro FJ, Blanco FJ. (2004). Pig chondrocyte xenografts for human chondral defect repair: an *in vitro* model. *Wound Repair Regen* 12:444-52.
- Fuentes-Boquete IM, Arufe Gonda MC, Díaz Prado S, Hermida Gómez T, de Toro Santos FJ, Blanco García FJ. (2007). Tratamiento de lesiones del cartílago articular con terapia celular. *Reumatol Clin* 3 Supl 3:S63-9.
- Fuentes-Boquete IM, Arufe Gonda MC, Díaz Prado SM, Hermida Gómez T, de Toro Santos FJ, Blanco FJ. (2008). Cell and tissue transplant strategies for joint lesions. *The Open Transplantation Journal* 2:21-8.
- Furukawa T, Eyre DR, Koide S, Glimcher MJ. (1980). Biochemical studies on repair cartilage resurfacing experimental defects in the rabbit knee. *J Bone Joint Surg Am* 62:79-89.
- Gelse K, von der Mark K, Schneider H. (2003). Cartilage regeneration by gene therapy. *Curr Gene Ther* 3:305-17.
- Giannini S, Buda R, Vannini F, Di Caprio F, Grigolo B. (2008). Arthroscopic autologous chondrocyte implantation in osteochondral lesions of the talus: surgical technique and results. *Am J Sports Med* 36:873-80.
- Gomez S, Toffanin R, Bernstorff S, Romanello M, Amenitsch H, Rappolt M, Rizzo R, Vittur F. (2000). Collagen fibrils are differently organized in weight-bearing and non-weight-bearing regions of pig articular cartilage. *J Exp Zool* 287:346-52.
- Gong Y, Ma Z, Zhou Q, Li J, Gao C, Shen J. (2008) Poly(lactic acid) scaffold fabricated by gelatin particle leaching has good biocompatibility for chondrogenesis. *J Biomater Sci Polym Ed* 19:207-21.
- Gooding CR, Bartlett W, Bentley G, Skinner JA, Carrington R, Flanagan A. (2006). A prospective, randomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: Periosteum covered versus type I/III collagen covered. *Knee* 13:203-10.

- Gouze E, Pawliuk R, Gouze JN, Pilapil C, Fleet C, Palmer GD, Evans CH, Leboulch P, Ghivizzani SC. (2003). Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation. *Mol Ther* 7:460-6.
- Grande DA, Singh IJ, Pugh J. (1987). Healing of experimentally produced lesions in articular cartilage following chondrocyte transplantation. *Anat Rec* 218:142-8.
- Grande DA, Pitman MI, Peterson L, Menche D, Klein M. (1989). The repair of experimentally produced defects in rabbit articular cartilage by autologous chondrocyte transplantation. *J Orthop Res* 7:208-18.
- Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortessidis A, Simmons PJ. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. *J Cell Sci* 116(Pt 9):1827-35.
- Gross AE, Shasha N, Aubin P. (2005). Long-term followup of the use of fresh osteochondral allografts for posttraumatic knee defects. *Clin Orthop Relat Res* 435:79-87.
- Haddo O, Mahroof S, Higgs D, David L, Pringle J, Bayliss M, Cannon SR, Briggs TW. (2004). The use of chondrocyte membrane in autologous chondrocyte implantation. *Knee* 11:51-5.
- Han SH, Kim YH, Park MS, Kim IA, Shin JW, Yang WI, Jee KS, Park KD, Ryu GH, Lee JK. (2008). Histological and biomechanical properties of regenerated articular cartilage using chondrogenic bone marrow stromal cells with a PLGA scaffold *in vivo*. *J Biomed Mater Res A* 87:850-61.
- Hangody L, Karpati Z. (1994). New possibilities in the management of severe circumscribed cartilage damage in the knee. *Magy Traumatol Ortop Kezseb Plasztikai Seb* 37:237-43.
- Hangody L, Feczkó P, Bartha L, Bodó G, Kish G. (2001). Mosaicplasty for the treatment of articular defects of the knee and ankle. *Clin Orthop Relat Res* (391 Suppl):S328-6.
- Hangody L, Fules P. (2003). Autologous osteochondral mosaicplasty for the treatment of full-thickness defects of weight-bearing joints: ten years of experimental and clinical experience. *J Bone Joint Surg Am* 85-A(Suppl 2):25-32.
- Hombach-Klonisch S, Panigrahi S, Rashedi I, Seifert A, Alberti E, Pocar P, Kurpisz M, Schulze-Osthoff K, Mackiewicz A, Los M. (2008). Adult stem cells and their trans-differentiation potential-perspectives and therapeutic applications. *J Mol Med* 86:1301-14.
- Im GI, Kim DY, Shin JH, Hyun CW, Cho WH. (2001). Repair of cartilage defect in the rabbit with cultured mesenchymal stem cells from bone marrow. *J Bone Joint Surg Br* 83:289-94.
- In't Anker PS, Noort WA, Kruisselbrink AB, Scherjon SA, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE. (2003). Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. *Exp Hematol* 31:881-9.
- Ishiguro N, Kojima T, Poole R. (2002). Mechanism of cartilage destruction in osteoarthritis. *Nagoya J Med Sci* 65:73-84.
- Iwasa J, Engebretsen L, Shima Y. (2009). Clinical application of scaffolds for cartilage tissue engineering. *Knee Surg Sports Traumatol Arthrosc* 17:561-77.
- Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, Bunnell BA. (2006). Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. *J Cell Biochem* 99:1285-97.
- Janjanin S, Li WJ, Morgan MT, Shanti RM, Tuan RS. (2008). Moldshaped, nanofiber scaffold-based cartilage engineering using human mesenchymal stem cells and bioreactor. *J Surg Res* 149:47-56.

- Jeon YH, Choi JH, Sung JK, Kim TK, Cho BC, Chung HY. (2007). Different effects of PLGA and chitosan scaffolds on human cartilage tissue engineering. *J Craniofac Surg* 18:1249-58.
- Jin CZ, Park SR, Choi BH, Lee KY, Kang CK, Min BH. (2007). Human amniotic membrane as a delivery matrix for articular cartilage repair. *Tissue Eng* 13:693-702.
- Johnson LL. (1986). Arthroscopic abrasion arthroplasty historical and pathologic perspective: present status. *Arthroscopy* 2:54-69.
- Jung DI, Ha J, Kang BT, Kim JW, Quan FS, Lee JH, Woo EJ, Park HM. (2009). A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury. *J Neurol Sci* 285:67-77.
- Jung M, Gotterbarm T, Gruettgen A, Vilei SB, Breusch S, Richter W. (2005). Molecular characterization of spontaneous and growth factor augmented chondrogenesis in periosteum-bone tissue transferred into a joint. *Histochem Cell Biol* 123:447-56.
- Kastrinaki M-C, Andreakou I, Charbord P, Papadaki HA. (2008). Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile. *Tissue Eng Part C Methods* 14:333-9.
- Kimura T, Yasui N, Ohsawa S, Ono K. (1984). Chondrocytes embedded in collagen gels maintain cartilage phenotype during long-term cultures. *Clin Orthop Relat Res* 186:231-9.
- Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO, Grøntvedt T, Solheim E, Strand T, Roberts S, Isaksen V, Johansen O. (2004). Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. *J Bone Joint Surg Am* 86-A:455-64.
- Koga H, Shimaya M, Muneta T, Nimura A, Morito T, Hayashi M, Suzuki S, Ju YJ, Mochizuki T, Sekiya I. (2008). Local adherent technique for transplanting mesenchymal stem cells as a potential treatment of cartilage defect. *Arthritis Res Ther* 10:R84.
- Korkala OL, Kuokkanen HO. (1995). Autoarthroplasty of knee cartilage defects by osteoperiosteal grafts. *Arch Orthop Trauma Surg* 114:253-6.
- Kreuz PC, Erggelet C, Steinwachs MR, Krause SJ, Lahm A, Niemeyer P, Ghanem N, Uhl M, Südkamp N. (2006a). Is microfracture of chondral defects in the knee associated with different results in patients aged 40 years or younger? *Arthroscopy* 22:1180-6.
- Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Südkamp N. (2006b). Results after microfracture of full-thickness chondral defects in different compartments in the knee. *Osteoarthritis Cartilage* 14:1119-25.
- Krishnan SP, Skinner JA, Carrington RW, Flanagan AM, Briggs TW, Bentley G. (2006). Collagen-covered autologous chondrocyte implantation for osteochondritis dissecans of the knee: two- to seven-year results. *J Bone Joint Surg Br* 88:203-5.
- Kuo CK, Li WJ, Mauck RL, Tuan RS. (2006). Cartilage tissue engineering: its potential and uses. *Curr Opin Rheumatol* 18:64-73.
- Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG. (2001). Circulating skeletal stem cells. *J Cell Biol* 153:1133-40.
- Langer F, Gross AE. (1974). Immunogenicity of allograft articular cartilage. *J Bone Joint Surg Am* 56:297-327.
- Le Blanc K, Götherström C, Ringdén O, Hassan M, McMahon R, Horwitz E, Anneren G, Axelsson O, Nunn J, Ewald U, Nordén Lindeberg S, Jansson M, Dalton A, Aström E, Westgren M. (2005). Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. *Transplantation* 79:1607-14.

- Lisignoli G, Cristino S, Piacentini A, Zini N, Noël D, Jorgensen C, Facchini A. (2006). Chondrogenic differentiation of murine and human mesenchymal stromal cells in a hyaluronic acid scaffold: differences in gene expression and cell morphology. *J Biomed Mater Res A* 77:497-506.
- Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. (1998). Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. *J Cell Physiol* 176:57-66.
- Mankin HJ. (1982). The response of articular cartilage to mechanical injury. *J Bone Joint Surg Am* 64:460-6.
- Marcacci M, Zaffagnini S, Kon E, Visani A, Iacono F, Loreti I. (2002). Arthroscopic autologous chondrocyte transplantation: technical note. *Knee Surg Sports Traumatol Arthrosc* 10:154-9.
- Mareschi K, Biasin E, Piacibello W, Aglietta M, Madon E, Fagioli F. (2001). Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. *Haematologica* 86:1099-100.
- Matikainen T, Laine J. (2005). Placenta-an alternative source of stem cells. *Toxicol Appl Pharmacol* 207 (2 Suppl):544-9.
- McCulloch PC, Kang RW, Sobhy MH, Hayden JK, Cole BJ. (2007). Prospective evaluation of prolonged fresh osteochondral allograft transplantation of the femoral condyle: minimum 2-year follow-up. *Am J Sports Med* 35:411-20.
- McGuckin CP, Forraz N, Baradez MO, Navran S, Zhao J, Urban R, Tilton R, Denner L. (2005). Production of stem cells with embryonic characteristics from human umbilical cord blood. *Cell Prolif* 38:245-55.
- Meller D, Pires RT, Mack RJ, Figueiredo F, Heiligenhaus A, Park WC, Prabhasawat P, John T, McLeod SD, Steuhl KP, Tseng SC. (2000). Amniotic membrane transplantation for acute chemical or thermal burns. *Ophthalmology* 107:980-9.
- Menche DS, Frenkel SR, Blair B, Watnik NF, Toolan BC, Yaghoubian RS, Pitman MI. (1996). A comparison of abrasion burr arthroplasty and subchondral drilling in the treatment of fullthickness cartilage lesions in the rabbit. *Arthroscopy* 12:280-6.
- Menche DS, Vangsness CT Jr, Pitman M, Gross AE, Peterson L. (1998). The treatment of isolated articular cartilage lesions in the young individual. *Instr Course Lect* 47:505-15.
- Metsaranta M, Kujala UM, Pelliniemi L, Osterman H, Aho H, Vuorio E. (1996). Evidence for insufficient chondrocytic differentiation during repair of full-thickness defects of articular cartilage. *Matrix Biol* 15:39-47.
- Minas T, Peterson L. (1997). Chondrocyte transplantation. *Oper Tech Orthop* 7:323-33.
- Minas T. (2001). Autologous chondrocyte implantation for focal chondral defects of the knee. *Clin Orthop Relat Res* 391:S349-61.
- Minguell JJ, Conget P, Erices A. (2000). Biology and clinical utilization of mesenchymal progenitor cells. *Braz J Med Biol Res* 33:881-7.
- Morton KE, Dewhurst CJ (1986). Human amnion in the treatment of vaginal malformations. *Br J Obstet & Gynaecol* 93:50-4.
- Mouw JK, Case ND, Guldberg RE, Plaas AH, Levenston ME. (2005). Variations in matrix composition and GAG fine structure among scaffolds for cartilage tissue engineering. *Osteoarthritis Cartilage* 13:828-36.
- Mrugala D, Dossat N, Ringe J, Delorme B, Coffy A, Bony C, Charbord P, Häupl T, Daures J-P, Noël D, Jorgensen C. (2009). Gene expression profile of multipotent mesenchymal stromal cells: identification of pathways common to TGF β 3/BMP2-induced chondrogenesis. *Cloning Stem Cells* 11:61-76.

- Muller B, Kohn D. (1999). Indication for and performance of articular cartilage drilling using the Pridie method. *Orthopade* 28:4-10.
- Muraglia A, Cancedda R, Quarto R. (2000). Clonal mesenchymal progenitors from human bone marrow differentiate *in vitro* according to a hierarchical model. *J Cell Sci* 113:1161-6.
- Murphy JM, Fink DJ, Hunziker EB, Barry FP. (2003). Stem cell therapy in a caprine model of osteoarthritis. *Arthritis Rheum* 48:3464-74.
- Nah HD, Swoboda B, Birk DE, Kirsch T. (2001). Type IIA procollagen: expression in developing chicken limb cartilage and human osteoarthritic articular cartilage. *Dev Dyn* 220:307-22.
- Nakagawa Y, Suzuki T, Kuroki H, Kobayashi M, Okamoto Y, Nakamura T. (2007). The effect of surface incongruity of grafted plugs in osteochondral grafting: a report of five cases. *Knee Surg Sports Traumatol Arthrosc* 15:591-6.
- Nakahara H, Bruder SP, Haynesworth SE, Holecek JJ, Baber MA, Goldberg VM, Caplan AI. (1990). Bone and cartilage formation in diffusion chambers by subcultured cells derived from the periosteum. *Bone* 11:181-8.
- Nettles DL, Elder SH, Gilbert JA. (2002). Potential use of chitosan as a cell scaffold material for cartilage tissue engineering. *Tissue Eng* 8:1009-16.
- Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian AM. (2008). Properties of the amniotic membrane for potential use in tissue engineering. *Eur Cell Mater* 15:88-99.
- Nishimori M, Deie M, Kanaya A, Exham H, Adachi N, Ochi M. (2006). Repair of chronic osteochondral defects in the rat. A bone marrowstimulating procedure enhanced by cultured allogenic bone marrow mesenchymal stromal cells. *J Bone Joint Surg Br* 88:1236-44.
- Nixon AJ, Sams AE, Lust G, Grande D, Mohammed HO. (1993). Temporal matrix synthesis and histological features of a chondrocyte-laden porous collagen cartilage analogue. *Am J Vet Res* 54:349-56.
- O'Driscoll SW, Fitzsimmons JS. (2000). The importance of procedure specific training in harvesting periosteum for chondrogenesis. *Clin Orthop Relat Res* (380):269-78.
- O'Driscoll SW, Fitzsimmons JS. (2001). The role of periosteum in cartilage repair. *Clin Orthop Rel Res* 391:S190-207.
- O'Driscoll SW, Saris DB, Ito Y, Fitzsimmons JS. (2001). The chondrogenic potential of periosteum decreases with age. *J Orthop Res* 19:95-103.
- Ohlendorf C, Tomford WW, Mankin HJ. (1996). Chondrocyte survival in cryopreserved osteochondral articular cartilage. *J Orthop Res* 14: 413-6.
- Oka M, Chang YS, Nakamura T, Ushio K, Toguchida J, Gu HO. (1997). Synthetic osteochondral replacement of the femoral articular surface. *J Bone Joint Surg Br* 79:1003-7.
- Palmer G, Pascher A, Gouze E, Gouze JN, Betz O, Spector M, Robbins PD, Evans CH, Ghivizzani SC. (2002). Development of gene-based therapies for cartilage repair. *Crit Rev Eukaryot Gene Expr* 12:259-73.
- Park J, Gelse K, Frank S, von der Mark K, Aigner T, Schneider H. (2006). Transgene-activated mesenchymal cells for articular cartilage repair: a comparison of primary bone marrow-, perichondrium/periosteum- and fat-derived cells. *J Gene Med* 8:112-25.
- Parsch D, Fellenberg J, Brummendorf TH, Eschlbeck AM, Richter W. (2004). Telomere length and telomerase activity during expansion and differentiation of human mesenchymal stem cells and chondrocytes. *J Mol Med* 82:49-55.

- Pasquinelli G, Tazzari P, Ricci F, Vaselli C, Buzzi M, Conte R. (2007). Ultrastructural characteristics of human mesenchymal stromal (stem) cells derived from bone marrow and term placenta. *Ultrastruc Pathol* 31:23-31.
- Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, Ochs BG, Aigner T, Richter W. (2006). Premature induction of hypertrophy during *in vitro* chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. *Arthritis Rheum* 54:3254-66.
- Pelttari K, Wixmerten A, Martin I. (2009). Do we really need cartilage tissue engineering? *Swiss Med Wkly* 139:602-9.
- Pérez-Cachafeiro S, Ruano-Raviña A, Couceiro-Follente J, Benedí-Alcaine JA, Nebot-Sanchis I, Casquete-Román C, Bello-Prats S, Couceiro-Sánchez G, Blanco FJ. (2010). Spanish experience in sutologous chondrocyte implantation. *Open Orthop* 4:14-21.
- Peterson L, Minas T, Brittberg M, Nilsson A, Sjogren-Jansson E, Lindahl A. (2000). Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. *Clin Orthop Relat Res* 374:212-34.
- Peterson L, Brittberg M, Kiviranta I, Akerlund EL, Lindahl A. (2002). Autologous chondrocyte transplantation. Biomechanics and long-term durability. *Am J Sports Med* 30:2-12.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. (1999). Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143-7.
- Pittenger MF. (2008). Mesenchymal stem cells from adult bone marrow. *Methods Mol Biol* 449:27-44.
- Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science* 276:71-4.
- Qiu YS, Shahgaldi BF, Revell WJ, Heatley FW. (2003). Observations of subchondral plate advancement during osteochondral repair: a histomorphometric and mechanical study in the rabbit femoral condyle. *Osteoarthritis Cartilage* 11:810-20.
- Rahfoth B, Weisser J, Sternkopf F, Aigner T, von der Mark K, Brauer R. (1998). Transplantation of allograft chondrocytes embedded in agarose gel into cartilage defects of rabbits. *Osteoarthritis Cartilage* 6:50-65.
- Ramallal M, Maneiro E, López E, Fuentes-Boquete I, López-Armada MJ, Fernández-Sueiro JL, Galdo F, de Toro FJ, Blanco FJ. (2004). Xeno-implantation of pig chondrocytes into rabbit to treat localized articular cartilage defects: an animal model. *Wound Repair Regen* 12:337-45.
- Rendal-Vázquez ME, Maneiro-Pampín E, Rodríguez-Cabarcos M, Fernández-Mallo O, López de Ullibarri I, Andión-Núñez C, Blanco FJ. (2001). Effect of cryopreservation on human articular chondrocyte viability, proliferation, and collagen expression. *Cryobiology* 42:2-10.
- Resinger C, Vécsei V, Marlovits S. (2004). Therapeutic options in the treatment of cartilage defects. Techniques and indications. *Radiologe* 44:756-62.
- Richardson JB, Caterson B, Evans EH, Ashton BA, Roberts S. (1999). Repair of human articular cartilage after implantation of autologous chondrocytes. *J Bone Joint Surg Br* 81:1064-8.
- Richler C, Yaffe D. (1970). The *in vitro* cultivation and differentiation capacities of myogenic cell lines. *Dev Bio*; 23:1-22.
- Rinastiti M, Harijadi, Santoso AL, Sosroseno W. (2006). Histological evaluation of rabbit gingival wound healing transplanted with human amniotic membrane. *Int J Oral Maxillofac Surg* 35:247-51.

- Roberts S, Hollander AP, Caterson B, Menage J, Richardson JB. (2001). Matrix turnover in human cartilage repair tissue in autologous chondrocyte implantation. *Arthritis Rheum* 44:2586-98.
- Robertson WB, Fick D, Wood DJ, Linklater JM, Zheng MH, Ackland TR. (2007). MRI and clinical evaluation of collagen-covered autologous chondrocyte implantation (CACI) at two years. *Knee* 14:117-27.
- Rogers BA, Murphy CL, Cannon SR, Briggs TW. (2006). Topographical variation in glycosaminoglycan content in human articular cartilage. *J Bone Joint Surg Br* 88:1670-4.
- Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. (2005). Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. *Arthritis Rheum* 52:2521-9.
- Sams AE, Minor RR, Wootton JA, Mohammed H, Nixon AJ. (1995). Local and remote matrix responses to chondrocyte-laden collagen scaffold implantation in extensive articular cartilage defects. *Osteoarthritis Cartilage* 3:61-70.
- Sams AE, Nixon AJ. (1995). Chondrocyte-laden collagen scaffolds for resurfacing extensive articular cartilage defects. *Osteoarthritis Cartilage* 3:47-59.
- Samuel GN, Kerridge IH, O'Brien TA. (2008). Umbilical cord blood banking: public good or private benefit? *Med J Aust* 188:533-5.
- Santos MS, Gomes JAP, Hofling-Lima AL, Rizzo LV, Romano AC, Belfort R Jr. (2005). Survival analysis of conjunctival limbal grafts and amniotic membrane transplantation in eyes with total limbal stem cell deficiency. *Am J Ophthalmol* 140:223-30.
- Schachar N, McAllister D, Stevenson M, Novak K, McGann L. (1992). Metabolic and biochemical status of articular cartilage following cryopreservation and transplantation: a rabbit model. *J Orthop Res* 10:603-9.
- Schreiber RE, Ilten-Kirby BM, Dunkelman NS, Symons KT, Rekettye LM, Willoughby J, Ratcliffe A. (1999). Repair of osteochondral defects with allogeneic tissue engineered cartilage implants. *Clin Orthop Rel Res* 367S:382-95.
- Shapiro F, Koide S, Glimcher MJ. (1993). Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 75:532-53.
- Sohn DH, Lottman LM, Lum LY, Kim SG, Pedowitz RA, Coutts RD, Sah RL. (2002). Effect of gravity on localization of chondrocytes implanted in cartilage defects. *Clin Orthop Relat Res* 394:254-62.
- Steadman JR, Rodkey WG, Briggs KK, Rodrigo JJ. (1999). The microfracture technic in the management of complete cartilage defects in the knee joint. *Orthopade* 28:26-32.
- Steadman JR, Briggs KK, Rodrigo JJ, Kocher MS, Gill TJ, Rodkey WG. (2003). Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. *Arthroscopy* 19:477-84.
- Teigman SA, Fauza DO. (2007). Isolation of mesenchymal stem cells from amniotic fluid and placenta. *Curr Protoc Stem Cell Biol*; Chapter 1:Unit 1E.2.
- Steinert AF, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Nöth U. (2007). Major biological obstacles for persistent cell-based regeneration of articular cartilage. *Arthritis Res Ther* 9:213.
- Steinwachs M, Kreuz PC. (2007). Autologous chondrocyte implantation in chondral defects of the knee with a type I/III collagen membrane: a prospective study with a 3-year follow-up. *Arthroscopy* 23:381-7.

- Stenderup K, Justesen J, Clausen C, Kassem M. (2003). Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. *Bone* 33:919-26.
- Szerb I, Hangody L, Duska Z, Kaposi NP. (2005). Mosaicplasty: long-term follow-up. *Bull Hosp Jt Dis* 63:54-62.
- Tejwani S, Kolar RS, Sangwan VS, Rao GN. (2007). Role of amniotic membrane graft for ocular chemical and thermal injuries. *Cornea* 26:21-6.
- Tins BJ, McCall IW, Takahashi T, Cassar-Pullicino V, Roberts S, Ashton B, Richardson J. (2005). Autologous chondrocyte implantation in knee joint: MR imaging and histologic features at 1-year follow-up. *Radiology* 234:501-8.
- Trippel SB, Ghivizzani SC, Nixon AJ. (2004). Gene-based approaches for the repair of articular cartilage. *Gene Ther* 11:351-9.
- Trzeciak T, Kruczynski J, Jaroszewski J, Lubiowski P. (2006). Evaluation of cartilage reconstruction by means of autologous chondrocyte versus periosteal graft transplantation: an animal study. *Transplant Proc* 38:305-11.
- Tsai MS, Hwang SM, Chen KD, Lee YS, Hsu LW, Chang YJ, Wang CN, Peng HH, Chang YL, Chao AS, Chang SD, Lee KD, Wang TH, Wang HS, Soong YK. (2007). Functional network analysis on the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. *Stem Cells* 25:2511-23.
- Tuli R, Li WJ, Tuan RS. (2003). Current state of cartilage tissue engineering. *Arthritis Res Ther* 5:235-8.
- Vachon A, McIlwraith CW, Trotter GW, Norrdin RW, Powers BE. (1989). Neochondrogenesis in free intra-articular, periosteal, and perichondrial autografts in horses. *Am J Vet Res* 50:1787-94.
- Van Susante JL, Wymenga AB, Buma P. (2003). Potential healing benefit of an osteoperiosteal bone plug from the proximal tibia on a mosaicplasty donor-site defect in the knee. An experimental study in the goat. *Arch Orthop Trauma Surg* 123:466-70.
- Villaron EM, Almeida J, Lopez-Holgado N, Alcoceba M, Sánchez-Abarca LI, Sanchez-Guijo FM, Alberca M, Pérez-Simon JA, San Miguel JF, Del Cañizo MC. (2004). Mesenchymal stem cells are present in peripheral blood and can engraft after allogenic haematopoietic stem cell transplantation. *Haematologica* 89:1421-7.
- Vinatier C, Mrugale D, Jorgensen C, Guicheux J, Noel D. (2009). Cartilage engineering: a crucial combination of cells, biomaterials and biofactors. *Trends Biotechnol* 27:307-14.
- Wakitani S, Kimura T, Hirooka A, Ochi T, Yoneda M, Yasui N, Owaki H, Ono K. (1989). Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. *J Bone Joint Surg Br* 71:74-80.
- Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. (2002). Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage* 10:199-206.
- Wong BJ, Pandhoh N, Truong MT, Diaz S, Chao K, Hou S, Gardiner D. (2005). Identification of chondrocyte proliferation following laser irradiation, thermal injury, and mechanical trauma. *Lasers Surg Med* 37:89-96.
- Xia Y, Moody JB, Alhadlaq H, Burton-Wurster N, Lust G. (2002). Characteristics of topographical heterogeneity of articular cartilage over the joint surface of a humeral head. *Osteoarthritis Cartilage* 10:370-80.

- Yanada S, Ochi M, Kojima K, Sharman P, Yasunaga Y, Hiyama E. (2006). Possibility of selection of chondrogenic progenitor cells by telomere length in FGF-2-expanded mesenchymal stromal cells. *Cell Prolif* 39:575-84.
- Yoo JU, Barthel TS, Nishimura K, Solchaga L, Caplan AI, Goldberg VM, Johnstone B. (1998). The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. *J Bone Joint Surg Am* 80:1745-57.
- You Q, Cai L, Zheng J, Tong X, Zhang D, Zhang Y. (2008). Isolation of human mesenchymal stem cells from third-trimester amniotic fluid. *Int J Gynaecol Obstet* 103:149-52.
- Young HE, Steele TA, Bray RA, Hudson J, Floyd JA, Hawkins K, Thomas K, Austin T, Edwards C, Cuzzourt J, Duenzl M, Lucas PA, Black AC Jr. (2001). Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. *Anat Rec* 264:51-62.
- Zarnett R, Salter RB. (1989). Periosteal neochondrogenesis for biologically resurfacing joints: its cellular origin. *Can J Surg* 32:171-4.
- Zimmermann S, Voss M, Kaiser S, Kapp U, Waller CF, Martens UM. (2003). Lack of telomerase activity in human mesenchymal stem cells. *Leukemia* 17:1146-9.
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 7:211-28.
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. (2002). Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 13:4279-95.
- Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, Maini RN. (2000). Mesenchymal precursor cells in the blood of normal individuals. *Arthritis Res* 2:477-88.

IntechOpen



Biomedical Engineering, Trends, Research and Technologies

Edited by Dr. Sylwia Olsztyńska

ISBN 978-953-307-514-3

Hard cover, 644 pages

Publisher InTech

Published online 08, January, 2011

Published in print edition January, 2011

This book is addressed to scientists and professionals working in the wide area of biomedical engineering, from biochemistry and pharmacy to medicine and clinical engineering. The panorama of problems presented in this volume may be of special interest for young scientists, looking for innovative technologies and new trends in biomedical engineering.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Silvia M Díaz Prado, Isaac Fuentes Boquete and Francisco J Blanco (2011). Cell Therapy and Tissular Engeneering to Regenerate Articular Cartilage, Biomedical Engineering, Trends, Research and Technologies, Dr. Sylwia Olsztyńska (Ed.), ISBN: 978-953-307-514-3, InTech, Available from:
<http://www.intechopen.com/books/biomedical-engineering-trends-research-and-technologies/cell-therapy-and-tissular-engeneering-to-regenerate-articular-cartilage>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](#), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen